|
|
|
Volumn 21, Issue 11, 2007, Pages
|
|
Is it time to reconsider subcutaneous administration of epoetin?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIANEMIC AGENT;
HEMOGLOBIN;
RECOMBINANT ERYTHROPOIETIN;
ANEMIA;
BIOAVAILABILITY;
CHRONIC KIDNEY FAILURE;
CLINICAL PRACTICE;
DRUG COST;
ECONOMICS;
EVIDENCE BASED MEDICINE;
HALF LIFE TIME;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MASS COMMUNICATION;
METABOLIC CLEARANCE RATE;
METABOLISM;
METHODOLOGY;
NEPHROLOGY;
ORGANIZATION AND MANAGEMENT;
PATIENT SELECTION;
PRACTICE GUIDELINE;
RENAL REPLACEMENT THERAPY;
REVIEW;
SUBCUTANEOUS DRUG ADMINISTRATION;
TREATMENT OUTCOME;
UNITED STATES;
ANEMIA;
BIOLOGICAL AVAILABILITY;
DIFFUSION OF INNOVATION;
DRUG COSTS;
EPOETIN ALFA;
EVIDENCE-BASED MEDICINE;
HALF-LIFE;
HEMATINICS;
HEMOGLOBINS;
HUMANS;
INJECTIONS, INTRAVENOUS;
INJECTIONS, SUBCUTANEOUS;
KIDNEY FAILURE, CHRONIC;
METABOLIC CLEARANCE RATE;
NEPHROLOGY;
PATIENT SELECTION;
PHYSICIAN'S PRACTICE PATTERNS;
PRACTICE GUIDELINES AS TOPIC;
RENAL DIALYSIS;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 38449112447
PISSN: 08961263
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (11)
|
|
References (31)
|
